Ultragenyx Pharmaceutical (RARE) is trading down at $16.48 (-4.30%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Current price targets from 2 firms average $50 — 203% above the current $16.5. Each is tracked to its date and scored the same way a member's call is.
2 targets, newest first. Open a row for its source and scoring.
Entry price $25.6, the close nearest Aug 28, 2026, when the target was reported; the target is +95% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 28, 2027.
Wells Fargo raised its price target on Ultragenyx Pharma stock (NASDAQ:RARE) to $50.00 from $46.00
Entry price $25.6, the close nearest Aug 28, 2026, when the target was reported; the target is +95% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 28, 2027.
H.C. Wainwright reiterated its Buy rating with a $50 price target
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $133.0K | $2.61M | $51.5M | $103.7M | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Growth (year over year) | — | +1863.9% | +1871.5% | +101.4% | +161.3% | +29.7% | +3.4% | +19.5% | +29.0% | +20.2% |
| Gross profit | — | $2.61M | $50.3M | — | — | — | — | — | — | — |
| Gross margin | — | 100.0% | 97.8% | — | — | — | — | — | — | — |
| Operating income | −$248.0M | −$328.9M | −$371.4M | −$424.2M | −$330.1M | −$381.7M | −$648.9M | −$569.0M | −$536.0M | −$535.0M |
| Operating margin | −186471.4% | −12593.5% | −721.2% | −409.0% | −121.8% | −108.6% | −178.6% | −131.1% | −95.7% | −79.5% |
| Net income | −$245.9M | −$302.1M | −$197.6M | −$402.7M | −$186.6M | −$454.0M | −$707.4M | −$607.0M | −$569.0M | −$575.0M |
| Net margin | −184867.7% | −11567.3% | −383.7% | −388.3% | −68.8% | −129.2% | −194.7% | −139.9% | −101.6% | −85.4% |
| EPS (diluted) | −$6.21 | −$7.12 | −$3.97 | −$7.12 | −$3.07 | −$6.70 | −$10.12 | −$8.25 | −$6.29 | −$5.83 |
| Balance sheet | ||||||||||
| Cash and equivalents | $161.1M | $100.5M | $113.4M | $433.6M | $713.5M | $307.6M | $132.9M | $214.0M | $174.0M | $421.0M |
| Total assets | $540.6M | $490.8M | $719.6M | $1.14B | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B | $1.53B |
| Total liabilities | $66.7M | $107.3M | $110.7M | $481.7M | $605.2M | $599.8M | $1.19B | $1.22B | $1.24B | $1.60B |
| Shareholders' equity | $474.0M | $383.5M | $608.9M | $653.8M | $1.15B | $922.6M | $352.0M | $275.0M | $255.0M | −$80.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$161.0M | −$253.8M | −$290.6M | −$345.4M | −$132.2M | −$338.7M | −$380.5M | −$475.0M | −$414.0M | −$466.0M |
| Capital expenditure | $10.2M | $2.79M | $4.08M | $24.8M | $43.9M | $73.1M | $116.1M | $44.0M | $7.00M | $6.00M |
| Free cash flow | −$171.2M | −$256.6M | −$294.6M | −$370.2M | −$176.1M | −$411.8M | −$496.6M | −$519.0M | −$421.0M | −$472.0M |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $164.6M | $139.0M | $167.0M | $160.0M | $207.0M | $136.0M | $214.0M | $173.0M |
| Growth (year over year) | +29.5% | +27.7% | +13.6% | +14.7% | +25.7% | −2.2% | +28.1% | +8.1% |
| Operating income | −$122.3M | −$143.0M | −$108.0M | −$171.0M | −$113.0M | −$169.0M | −$75.0M | −$110.0M |
| Operating margin | −74.3% | −102.9% | −64.7% | −106.9% | −54.6% | −124.3% | −35.0% | −63.6% |
| Net income | −$133.2M | −$151.0M | −$115.0M | −$180.0M | −$129.0M | −$185.0M | −$92.0M | −$118.0M |
| Net margin | −80.9% | −108.6% | −68.9% | −112.5% | −62.3% | −136.0% | −43.0% | −68.2% |
| EPS (diluted) | −$1.38 | −$1.57 | −$1.17 | −$1.81 | −$1.28 | −$1.84 | −$0.90 | −$1.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $174.0M | $127.0M | $176.0M | $203.0M | $421.0M | $175.0M | $125.0M | $150.0M |
| Total assets | $1.50B | $1.31B | $1.31B | $1.19B | $1.53B | $1.30B | $1.26B | $1.19B |
| Total liabilities | $1.24B | $1.16B | $1.15B | $1.17B | $1.60B | $1.52B | $1.55B | $1.56B |
| Shareholders' equity | $255.0M | $144.0M | $151.0M | $10.0M | −$80.0M | −$236.0M | −$291.0M | −$376.0M |
| Cash flow | ||||||||
| Operating cash flow | −$79.3M | −$166.0M | −$109.0M | −$91.0M | −$100.0M | −$197.0M | −$97.0M | −$43.0M |
| Capital expenditure | $163.0K | $1.00M | $3.00M | $1.00M | $1.00M | $1.00M | $1.00M | $2.00M |
| Free cash flow | −$79.5M | −$167.0M | −$112.0M | −$92.0M | −$101.0M | −$198.0M | −$98.0M | −$45.0M |
From Ultragenyx Pharmaceutical's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Read at The Motley Fool ↗ Link to this story
Also mentions USA Rare Earth Inc Class a
Read at Barchart.com ↗ Link to this story
Also mentions Apple Inc.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Source: Wikipedia — Ultragenyx